Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copy of Investor Presentation for the quarter ended December 31, 2022. Q3FY23 Quarterly Result Announced for Metropolis Healthcare Ltd.
Metropolis Healthcare announced Q3FY23 results: Q3FY23 & 9MFY23: Non-Covid growth stood at 13% for Q3FY23 & 15% for 9MFY23 on YoY basis (excl. revenues for PPP Contracts & Hi-tech acquisition) Volume growth for Q3FY23 stood at 10% & RPP growth stood at 3% on a YoY basis (excl. volumes for PPP Contracts & Hi-tech acquisition) Operating EBIDTA for Q3FY23 stood at 28.3%, dilution of ~120 bps on account of Lab addition & Network expansion. New Network has contributed ~3% of Revenues for Q3FY23. EBIDTA margin (before CSR & ESOP) stood at 27.1% Revenue from North & East combined grew by 29% for Q3FY23 on a YoY basis Revenue growth for B2C in focus cities stood at 16% for Q3FY23 & 25% for 9MFY23 on a YoY basis; Mumbai & Pune are growing at a faster pace indicating our strength & market share penetration in the core geographies Our Specialized & Wellness segments are the fastest growing segment for Q3FY23 indicating strong Brand Equity & Doctor’s Trust in Metropolis Brand The board has declared an interim dividend of Rs 8 per equity share of Face value of Rs 2 each to equity shareholders of the company. “We are delighted to report 20% YoY growth in Non-Covid revenues for Q3FY23. We have delivered consistent growth in Non-Covid revenues for the last 4 quarters on the back of strong on-ground execution, our scientific approach to diagnostics, and the steady industry shift of volumes from unorganised sector to organised sector. The growth was across parameters – volume, core geographies, non-Core geographies, wellness segments thus indicating the brand equity & quality of services across the country. Revenues for North & East grew ~29% YoY in Q3FY23. We remain confident of sustaining this growth going forward. Revenue contribution from wellness segment increased to 13% in Q3FY23 & witnessed a healthy growth of 30% YoY. Metropolis is a diagnostic specialist and our strategy of faster growth in Specialised & wellness segment continues to remain on track.” Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd. Result PDF Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below: 'Metropolis Healthcare Ltd. Non-Covid Revenues at Rs. 278 crs in Q3FY23; up by 20% YoY' Metropolis Healthcare Ltd - 542650 - Metropolis Healthcare Limited Has Informed The Exchange That Record Date For The Purpose Of Declaring Interim Dividend Is 23-Feb-2023
This is to inform you that the Board of Directors of the Company at their Meeting held today i.e. Friday, February 10, 2023 have inter-alia: i. Approved and Declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight Only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two Only) per Equity Share for the Financial Year 2022-23. The Board has fixed Thursday, February 23, 2023, as the 'Record Date' for the purpose of ascertaining eligibility of the shareholders for payment of Interim Dividend. The Interim Dividend will be paid to the shareholders within 30 days of declaration. Metropolis Healthcare Ltd - 542650 - Corporate Action-Board approves Dividend
This is to inform you that the Board of Directors of the Company at their Meeting held today i.e. Friday, February 10, 2023 have inter-alia: i. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022 and noted the Limited Review Report. The Copy of the Unaudited Standalone & Consolidated Financial Results of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter and nine months ended December 31, 2022 is enclosed herewith as Annexure - 1. ii. Approved and Declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight Only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two Only) per Equity Share for the Financial Year 2022-23. The Board has fixed Thursday, February 23, 2023, as the 'Record Date'. The Interim Dividend will be paid to the shareholders within 30 days of declaration. Metropolis Healthcare Ltd - 542650 - Outcome Of Board Meeting Held On Friday, February 10, 2023
This is to inform you that the Board of Directors of the Company at their Meeting held today i.e. Friday, February 10, 2023 have inter-alia: i. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022 and noted the Limited Review Report The Copy of the Unaudited Standalone & Consolidated Financial Results of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter and nine months ended December 31, 2022 is enclosed herewith as Annexure - 1. ii. Approved and Declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight Only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two Only) per Equity Share for the Financial Year 2022-23. The Board has fixed Thursday, February 23, 2023, as the 'Record Date'. The Interim Dividend will be paid to the shareholders within 30 days of declaration. Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), we would like to inform you that the Company will participate in the Q3FY23 Earnings Conference Call (i.e. Post Earnings/Quarterly Call), as organized by JM Financial Institutional Securities Limited on Monday, February 13, 2023 at 9:00 a.m. (IST) to discuss the financial results of the Company for the quarter ended December 31, 2022, as per details enclosed herewith. Metropolis Healthcare Ltd - 542650 - Board Meeting Intimation for Intimation Of Notice Of Board Meeting Scheduled To Be Held On Friday, February 10, 2023
Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 ,inter alia, to consider and approve We wish to inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on Friday, February 10, 2023, to inter alia, 1. Consider and approve Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022; 2. Consider and approve the declaration of Interim Dividend for the Financial Year 2022-23, if any. The Record Date for the purpose of Interim Dividend, if declared, will be February 24, 2023. Further, we also wish to inform you that in terms of the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company has been closed for the Designated Persons of the Company and their immediate relatives with effect from January 01, 2023 and shall re-open 48 hours after the declaration of the Financial Results of the Company for the quarter ended December 31, 2022. Metropolis Healthcare Ltd - 542650 - Intimation Of Certified True Copy Of Order Issued By Hon'Ble National Company Law Tribunal, Mumbai Bench With Respect To Withdrawal Of Petition Filed By Operational Creditors
This is in continuation to our letter bearing reference No. MHL/Sec. & Legal/2022-23/85 dated January 23, 2023 with respect to intimation of Order (Uncertified) issued by Hon'ble National Company Law Tribunal, Mumbai Bench, Court-II ('NCLT') pertaining to withdrawal of Petition filed by Operational Creditors in the matter of Mr. Vinod Lath v/s Metropolis Healthcare Ltd and Dr. Bharat Gupta v/s M/s. Metropolis Healthcare Limited which was amicably settled between the parties. In this regard we wish to inform you that, the Company has received the Certified True Copy of the said orders from NCLT. The same is enclosed for your records. Metropolis Healthcare Ltd - 542650 - Intimation W.R.T Withdrawal Of Petition Filed By Operational Creditors
Pursuant to Point No.16(c) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as per the direction given by National Stock Exchange of India Limited ('NSE'), this is to inform you that, the matter listed with National Company Law Tribunal, Mumbai Bench, Court -II ('NCLT') namely Mr. Vinod Lath v/s Metropolis Healthcare Ltd and Dr. Bharat Gupta v/s M/s. Metropolis Healthcare Limited were amicably settled between the parties. Consequently, the above-mentioned petitions have been withdrawn by respective petitioners and the said petitions have been disposed off by NCLT. The withdrawal order of NCLT is attached for your ready reference. Further, please note that the Company is awaiting for certified copy of the said orders